Search

Now showing items 1-10 of 17

HIV vaccines and immunity.

Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Allergy Society of South Africa., 2003)

No abstract available.

Topical microbicides - What's new?

Abdool Karim, Quarraisha.; Baxter, Cheryl.; Abdool Karim, Salim Safurdeen. (Lippincott Williams & Wilkins., 2013)

Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...

Using mobile technology (pMOTAR) to assess reactogenicity: protocol for a pilot randomized controlled trial.

Mngadi, Kathryn Therese.; Maharaj, Bhavna.; Duki, Yajna.; Grove, Douglas.; Andriesen, Jessica. (JMIR Publications., 2018)

Abstract available in pdf.

Preservation HIV-1–specific IFNg+ CD4+ T-Cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.

Mureithi, Marianne W.; Poole, Danielle.; Naranbhai, Vivek.; Reddy, Shabashini.; Mkhwanazi, Nompumelelo Prudence.; Sibeko, Sengeziwe.; Werner, Lise.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Ndung'u, Peter Thumbi.; Altfeld, Marcus. (Lippincott Williams & Wilkins., 2011)

Abstract: The Centre for the AIDS Program of Research in South Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition in women using a vaginal microbicide containing tenofovir. A better understanding of the ...

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Gengiah, Tanuja Narayansamy.; Moosa, Atika.; Naidoo, Anushka.; Mansoor, Leila Essop. (Springer Verlag., 2013)

Background: There are 34 million people living with human immunodeficiency virus (HIV) worldwide and each year this number increases. Until a vaccine is discovered, the prevention of new HIV infections remains an urgent ...

Comparison of viral env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Ping, Li-Hua.; Joseph, Sarah B.; Anderson, Jeffrey A.; Abrahams, Melissa-Rose.; Salazar-Gonzalez, Jesus F.; Kincer, Laura P.; Treurnicht, Florette K.; Arney, Leslie.; Ojeda, Suany.; Zhang, Ming.; Keys, Jessica.; Potter, E. Lake.; Chu, Haitao.; Moore, Penelope L.; Salazar-Gonzalez, Maria.; Iyer, Shilpa.; Jabara, Cassandra.; Kirchherr, Jennifer.; Mapanje, Clement.; Ngandu, Nobubelo K.; Seoighe, Cathal.; Hoffman, Irving F.; Gao, Feng.; Tang, Yuyang.; Labranche, Celia.; Lee, Benhur.; Saville, Andrew.; Vermeulen, Marion.; Fiscus, Susan A.; Morris, Lynn.; Abdool Karim, Salim Safurdeen.; Haynes, Barton F.; Shaw, George M.; Korber, Bette T. M.; Hahn, Beatrice H.; Cohen, Myron S.; Montefiori, David Charles.; Williamson, Carolyn.; Swanstrom, Ronald. (American Society for Microbiology., 2013)

Understanding human immunodeficiency virus type 1 (HIV-1) transmission is central to developing effective prevention strategies, including a vaccine.We compared phenotypic and genetic variation in HIV-1 env genes from ...

Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.

Wecker, M.; Gilbert, Peter B.; Russell, N.; Hural, J.; Allen, Mary.; Pensiero, M.; Chulay, J.; Chiu, Ya-Lin.; Abdool Karim, Salim Safurdeen.; Burke, D. S. (American Society for Microbiology., 2012)

On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, ...

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate Human Immunodeficiency Virus Type 1 vaccines.

Mascola, John R.; D'Souza, Patricia.; Gilbert, Peter B.; Hahn, Beatrice H.; Haigwood, Nancy L.; Morris, Lynn.; Petropoulos, Christos J.; Polonis, Victoria R.; Sarzotti, Marcella.; Montefiori, David Charles. (American Society for Microbiology., 2005)

No abstract available.

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Archary, Derseree.; Rong, Rong.; Gordon, Michelle Lucille.; Boliar, Saikat.; Madiga, Maphuti C.; Gray, Elin Solomonovna.; Dugast, Anne-Sophie.; Hermanus, Tandile.; Goulder, Philip Jeremy Renshaw.; Coovadia, Hoosen Mahomed.; Werner, Lise.; Morris, Lynn.; Alter, Galit.; Derdeyn, Cynthia A.; Ndung'u, Peter Thumbi. (Elsevier., 2012)

Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically ...

The development of CD4 binding site antibodies during HIV-1 infection.

Lynch, Rebecca M.; Tran, Lillian.; Louder, Mark K.; Schmidt, Stephen D.; Cohen, Myron S.; DerSimonian, Rebecca.; Euler, Zelda.; Gray, Elin Solomonovna.; Abdool Karim, Salim Safurdeen.; Kirchherr, Jennifer.; Montefiori, David Charles.; Sibeko, Sengeziwe.; Soderberg, Kelly.; Tomaras, Georgia D.; Yang, Zhi-Yong.; Nabel, Gary J.; Schuitemaker, Hanneke.; Morris, Lynn.; Haynes, Barton F.; Mascola, John R. (American Society for Microbiology., 2012)

Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individuals, but little is known about the prevalence and evolution of this antibody response during the course ...